Cargando…

Second primary malignancy in patients with esophageal adenocarcinoma and squamous cell carcinoma

There have been no studies on implementing effective screening models for esophageal adenocarcinoma and squamous cell carcinoma survivors. We used a proportional subdistribution hazards model to estimate second primary malignancy risks among patients with esophageal adenocarcinoma and squamous cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Guoqing, Wu, Bin, Wang, Xiaofei, Li, Jindong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738979/ https://www.ncbi.nlm.nih.gov/pubmed/31490413 http://dx.doi.org/10.1097/MD.0000000000017083

Ejemplares similares

Concurrent chemoradiotherapy with raltitrexed and nedaplatin regimen for esophageal squamous cell carcinoma
por: Qiu, Xiangnan, et al.
Publicado: (2020)

Lymphopenia Predicts Poor Prognosis in Patients With Esophageal Squamous Cell Carcinoma
por: Feng, Ji-Feng, et al.
Publicado: (2014)

High expression of PDGFA predicts poor prognosis of esophageal squamous cell carcinoma
por: Han, Na, et al.
Publicado: (2021)

Impact of Treatment Modalities on Survival of Patients With Locoregional Esophageal Squamous-Cell Carcinoma in Taiwan
por: Chen, Hui-Shan, et al.
Publicado: (2016)

Real-world treatment patterns and survival for locally advanced esophageal squamous cell carcinoma
por: Luo, Hua-Chun, et al.
Publicado: (2023)

Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma: A case report
por: Vanni, Irene, et al.
Publicado: (2016)

A nomogram based on hematological markers to predict radiosensitivity in patients with esophageal squamous cell carcinoma
por: Sun, Lijun, et al.
Publicado: (2023)

Expression and prognostic value of AIM1L in esophageal squamous cell carcinoma
por: Zhou, Lu, et al.
Publicado: (2023)

Postoperative radiotherapy for the young–old patients with thoracic esophageal squamous cell carcinoma: A 2-center experience
por: Ding, Wei, et al.
Publicado: (2020)

High expression of cytokeratin CAM5.2 in esophageal squamous cell carcinoma is associated with poor prognosis
por: He, Shujin, et al.
Publicado: (2019)

Network module function enrichment analysis of lung squamous cell carcinoma and lung adenocarcinoma
por: Li, Piaopiao, et al.
Publicado: (2022)

Expression of SIRT1 and survivin correlates with poor prognosis in esophageal squamous cell carcinoma
por: Yan, Li, et al.
Publicado: (2020)

High FN1 expression is associated with poor survival in esophageal squamous cell carcinoma
por: Ma, Junliang, et al.
Publicado: (2022)

Trefoil Factor 3 as a Novel Biomarker to Distinguish Between Adenocarcinoma and Squamous Cell Carcinoma
por: Wang, Xiao-Nan, et al.
Publicado: (2015)

Poorer prognosis in patients with advanced gastric squamous cell carcinoma compared with adenocarcinoma of the stomach: Case report
por: Meng, Ying, et al.
Publicado: (2017)

Circulating Tumor Cell Analyses in Patients With Esophageal Squamous Cell Carcinoma Using Epithelial Marker-Dependent and -Independent Approaches
por: Li, Hao, et al.
Publicado: (2015)

Prognostic value of neutrophil-to-lymphocyte ratio in peripheral blood and pathological tissue in patients with esophageal squamous cell carcinoma
por: Guo, Quanquan, et al.
Publicado: (2020)

The role of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 in esophageal squamous cell carcinoma
por: Bao, Junhui, et al.
Publicado: (2020)

High-dose radiation therapy alone by moderate hypofractionation for patients with thoracic esophageal squamous cell carcinoma
por: Oh, Dongryul, et al.
Publicado: (2016)

Circulating uPA as a potential prognostic biomarker for resectable esophageal squamous cell carcinoma
por: He, Xiao, et al.
Publicado: (2019)

Common gene signatures and key pathways in hypopharyngeal and esophageal squamous cell carcinoma: Evidence from bioinformatic analysis
por: Zhou, Rui, et al.
Publicado: (2020)

The efficacy and safety of sintilimab combined with chemotherapy as the first-line treatment for metastatic esophageal squamous cell carcinoma
por: Zhao, Zheng, et al.
Publicado: (2023)

Factors Associated With False-Negative Endoscopic Biopsy Results After Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma
por: Chao, Yin-Kai, et al.
Publicado: (2015)

Prognostic impact of eosinophils in peripheral blood and tumor site in patients with esophageal squamous cell carcinoma treated with concurrent chemoradiotherapy
por: Yang, Xiyue, et al.
Publicado: (2021)

Better survival and prognosis in SCLC survivors after combined second primary malignancies: A SEER database-based study
por: Wang, Silin, et al.
Publicado: (2023)

Effects of preoperative radiotherapy on survival of patients with stage II and III esophageal squamous cell carcinoma: A population-based study
por: Dong, Jing, et al.
Publicado: (2021)

Incidence of Second Primary Malignancies Following Colorectal Cancer: A Distinct Pattern of Occurrence Between Colon and Rectal Cancers and Association of Co-Morbidity with Second Primary Malignancies in a Population-Based Cohort of 98,876 Patients in Taiwan
por: Lee, Yu-Ting, et al.
Publicado: (2015)

Treatment of primary squamous cell carcinoma of the endometrium and review of previous literature: A case report
por: Song, Liyun, et al.
Publicado: (2023)

Hot food and beverage consumption and the risk of esophageal squamous cell carcinoma: A case-control study in a northwest area in China
por: Tai, Wei-Ping, et al.
Publicado: (2017)

Microvessel density as a prognostic factor in esophageal squamous cell cancer patients: A meta-analysis
por: Ma, Guangzhi, et al.
Publicado: (2017)

Efficacy of albumin-bound paclitaxel combined with nedaplatin in neoadjuvant therapy for esophageal squamous cell carcinoma: A single-center retrospective observational study
por: Chen, Jiakuan, et al.
Publicado: (2023)

A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma
por: Tang, Yong, et al.
Publicado: (2019)

Intensity-modulated radiotherapy with more than 60 Gy improved the survival of inoperable patients with locally advanced esophageal squamous cell carcinoma: A population-based real-world study
por: Zhang, Wei, et al.
Publicado: (2022)

Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma
por: Zhang, Dandan, et al.
Publicado: (2022)

Clinical outcomes of elderly patients (≥70 years) with resectable esophageal squamous cell carcinoma who underwent esophagectomy or chemoradiotherapy: A retrospective analysis from a single cancer institute
por: Jing, Wang, et al.
Publicado: (2016)

Predictive value of preoperative serum squamous cell carcinoma antigen level for lymph node metastasis in early-stage cervical squamous cell carcinoma
por: Zhu, Chenggong, et al.
Publicado: (2021)

The long-term impact of tumor burden in pT3N0M0 esophageal squamous cell carcinoma: A propensity score-matched analysis
por: Li, Tingting, et al.
Publicado: (2019)

Spindle cell carcinoma of the esophagus: A multicenter analysis in comparison with typical squamous cell carcinoma
por: Zhang, Baihua, et al.
Publicado: (2016)

Predictive Value of Serum miR-10b, miR-29c, and miR-205 as Promising Biomarkers in Esophageal Squamous Cell Carcinoma Screening
por: Xu, Hang, et al.
Publicado: (2015)

Clinical outcome in lung cancer with a second malignancy: The time sequence matters
por: Lu, Ming-Shian, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_gq72ocphdsehpjcn2u5aath8b7